Fluoxetine and reversal of multidrug resistance

Cancer Letters

Volumn 237, Issue 2, 2006, Pages 180-187

  Peer, Dan ^a,b   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ABC transporters; Chemosensitizers; Chemotherapy; Fluoxetine; Multidrug resistance (MDR)

Indexed keywords

ABC TRANSPORTER; ANTIDEPRESSANT AGENT; BIRICODAR; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; FLUOXETINE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROBENECID; PROGESTERONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TARIQUIDAR; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

CANCER STEM CELL; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG ACCUMULATION; DRUG INHIBITION; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; TUMOR GROWTH;

EID: 33646825806     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.003     Document Type: Review

References (46)

1. Gotttesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Can. 2 (2002) 48-58
2. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58 (2001) 931-959
3. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
4. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
5. Fojo T., and Bates S. Strategies for reversing drug resistance. Oncogene 22 (2003) 7512-7523
6. Biganzoli L., Minisini A., Aapro M., and Di Leo A. Chemotherapy for metastatic breast cancer. Curr. Opin. Obstet. Gynecol. 6 (2004) 37-41
7. Smith I.E. New drugs for breast cancer. Lancet 360 (2002) 790-792
8. Leonssa F., and Clarke R. ATP-binding cassette transporters and drug resistance in breast cancer. Endocrine-Relat. Cancer 10 (2003) 43-73
9. Dahl S.G., Sylte I., and Ravna A.W. Structures and models of transporter proteins. J. Pharmacol. Expl. Ther. 309 (2004) 853-860
10. Jones P.M., and George A.M. The ABC transporter structure and mechanism: perspectives on recent research. Cell. Mol. Life Sci. (2004) 61682-61699
11. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005) 275-284
12. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer and cancer stem cells. Nature 414 (2001) 105-111
13. Hegedus T., Orfi L., Seprodi A., Varadi A., Sarkadi B., and Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587 (2002) 318-325
14. Bornhauser M., Illmer T., Le Coutre P., Pursche J., von Bonin M., Freiberg-Richter J., et al. Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. Ann. Hematol. 83 Suppl. 1 (2004) S61-S64
15. Roskoski Jr. R. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 309 (2003) 709-717
16. Beger H.G., Rau B., Gansauge F., Poch B., and Link K.H. Treatment of Pancreatic cancer: challenge of the facts. World J. Surg. 27 (2003) 1075-1084
17. Willet C.G., and Clark J.W. Update on combined-modality treatment options for pancreatic cancer. Oncology 17 (2003) 29-36
18. Tsuruo T., Lida H., Nojri M., Tsukagoshi S., and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 (1981) 1967-1972
19. Yung Y.B., Chang F.J., and Bor A.M. Modulation of the reversibility of actinomycin D cytotoxicity in HeLa cells by verapamil. Cancer Lett. 60 (1991) 221-227
20. Foxwell B.M.J., Mackie A., Ling V., and Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Mol. Pharmcol. 36 (1989) 543-546
21. Twentyman P.R., Fox N.H., White, and Cyclosporin D.J. A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br. J. Cancer 56 (1987) 55-57
22. Naito M., Yusa K., and Tsuruo T. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem. Biophys. Res. Comm. 158 (1989) 1066-1071
23. Yang C.P., DePinoho S.G., Greenberger L.M., Arceci J.R., and Horwitz S.B. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem. 264 (1989) 782-788
24. Zhang C., Sarshar S., Moran E.J., Krane S., Rodarte J.C., Benbatoul K.D., et al. 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2. Bioorg. Med. Chem. Lett. 10 (2000) 2603-2605
25. Stewart A., Steiner J., Mellows G., Laguda B., Norris D., and Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res. 6 (2000) 4186-4191
26. Naito M., Matsuba Y., Sato S., Hirata H., and Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin. Cancer Res. 8 (2002) 582-588
27. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9 (2003) 650-656
28. Seiden M.V., Swenerton K.D., Matulonis U., Campos S., Rose P., Batist G., et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. 86 (2002) 302-310
29. Toppmeyer D., Seidman A.D., Pollak M., Russell C., Tkaczuk K., Verma S., et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8 (2002) 670-678
30. Germann U.A., Shlyakhter D., Mason V.S., Zelle R.E., Duffy J.P., Galullo V., et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8 (1997) 125-140
31. Atadja P., Watanabe T., Xu H., and Cohen D. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev. 17 (1998) 163-168
32. Dale I.L., Tuffley W., Callaghan R., Holmes J.A., Martin K., Luscombe M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br. J. Cancer 78 (1998) 885-892
33. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 (1993) 4595-4602
34. Starling J.J., Shepard R.L., Cao J., Law K.L., Norman B.H., Kroin J.S., et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv. Enzyme Regul. 37 (1997) 335-347
35. Guns E.S., Denyssevych T., Dixon R., Bally M.B., and Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093-a new modulator of MDR in cancer chemotherapy. Eur. J. Drug Metab. Pharmacokinet. 27 (2002) 119-126
36. Chauvier D., Kegelaer G., Morjani H., and Manfait M. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J. Pharmacol. Sci. 91 (2002) 1765-1775
37. Robey R.W., Steadman K., Polgar P., Morisaki K., Blayney M., Mistry P., and Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64 (2004) 1242-1246
38. Stein U., Lage H., Jordan A., Walther W., Bates S.E., Litman L., et al. Impact of BCRP/MXR and MDR1/P-glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int. J. Can. 97 (2002) 751-760
39. Abe T., Koike K., Ohga T., Kubo T., Wada M., Kohno K., et al. Chemosensitization of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br. J. Can. 72 (1995) 418-423
40. Shapiro A.B., and Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol. Scand. Suppl. 643 (1998) 227-234
41. Saengkhae C., Loetchutinat C., and Garnier-Suillerot A. Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1). Biophys. J. 85 (2003) 2006-2014
42. Nordenberg J., Fenig E., Landau M., Weizman R., and Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem. Pharmacol. 58 (1999) 1229-1236
43. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101 (2003) 3212-3219
44. Peer D., Dekel Y., Melikhov D., and Margalit R. Fluoxetine inhibits MDR extrusion pumps and enhances therapeutic responses to chemotherapy in syngeneic and human xenograft mouse tumor models. Cancer Res. 64 (2004) 7562-7569
45. D. Peer, S. Bransburg-Zabary, Y. Dekel, D. Melikhov, R. Margalit, Fluoxetine-modulation of inherent drug resistance in human MRP1 (ABCC1): in vitro, in vivo and in silico studies, Submitted for publication.
46. J. Weiss, S.M. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, W.E. Haefeli, Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Expl. Ther. 305 (2003)197-204.